Arbutus Biopharma (ABUS) FCF Margin (2016 - 2025)
Historic FCF Margin for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 1099.62%.
- Arbutus Biopharma's FCF Margin rose 4490000.0% to 1099.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 310.54%, marking a year-over-year increase of 7562500.0%. This contributed to the annual value of 1053.83% for FY2024, which is 5745600.0% down from last year.
- Arbutus Biopharma's FCF Margin amounted to 1099.62% in Q3 2025, which was up 4490000.0% from 146.65% recorded in Q2 2025.
- In the past 5 years, Arbutus Biopharma's FCF Margin registered a high of 163.29% during Q1 2022, and its lowest value of 1548.62% during Q3 2024.
- Moreover, its 5-year median value for FCF Margin was 613.35% (2021), whereas its average is 609.92%.
- Per our database at Business Quant, Arbutus Biopharma's FCF Margin surged by 10142200bps in 2022 and then tumbled by -10802600bps in 2024.
- Arbutus Biopharma's FCF Margin (Quarter) stood at 613.35% in 2021, then soared by 55bps to 274.2% in 2022, then tumbled by -194bps to 806.15% in 2023, then rose by 18bps to 660.8% in 2024, then crashed by -66bps to 1099.62% in 2025.
- Its last three reported values are 1099.62% in Q3 2025, 146.65% for Q2 2025, and 759.13% during Q1 2025.